1688-0420

S1688-04202021000101304

10.29277/cardio.36.1.7

Uruguay

00 04 2021

36 1

O'Connell E.Ballot J.Geraghty L.Fennelly D 2016 156 3 3

501-6

2013 49 6 6

1374-403

2012 62 4 4

220-41

American Society of Clinical Oncology

2015

2016 66 4 4

271-89

2013 31 29 29

3673-80

2016 66 4 4

309-25

2013 35 2 2

37-47

ESC Scientific Document Group 2016 37 36 36

2768-801

2002 20 5 5

1215-21

2016 22 6 6

465-71

2016 1 9 9

1066-72

2018 13 1 1

64-9

1996 125 1 1

47-58

2015 131 22 22

1981-8

2019 10 2 2

van der Pal H.Caron H 2015 33 32 32

3774-80

2017 12 9 9

2018 38

3-12

2013 65 5 5

631-2

2014 3 2 2

2018 1 1 1

13-7

2012 2012 4 4

CD006243

2013 18 3 3

257-64

2020 126

65-73

2018 26 3 3

122-9

2019 133 7 7

626-8

2016 18 6 6

2016 128 1 1

138-40

2019 16 9 9

1374-82

2015 6 34 34

35589-601

2019 381 7 7

626-36

2014 371 20 20

1867-76

2017 53

120-7

2016 375 18 18

1749-55

2019 33 6 6

613-20

2016 23 2 2

104-11

2017 70 6 6

474-86

2015 28 1 1

1-39

2015 16 9 9

977-84

2012 30 31 31

3792-9

2014 89 9 9

1287-306

2014 27 9 9

911-39

ESC Scientific Document Group 2016 37 27 27

2129-200

2016 2 1 1

2015 65 25 25

2739-46

2017 70 7 7

583-9

CPNDS Clinical Practice Recommendations Group 2016 82 3 3

683-95

2018 20 7 7

2015 116 3 3

442-6

2017 35 8 8

893-911

2003 97 11 11

2869-79

2015 175 6 6

1007-17

2011 118 23 23

6023-9

2004 91 1 1

45-9

2004 22 15 15

3070-9

2006 17 1 1

85-92

2008 100 15 15

1058-67

2008 26 34 34

5537-43

2016 34 10 10

1122-30

Pharmacovigilance Study Team 2012 104 17 17

1293-305

St John Sutton M.Holme I 1997 18 3 3

507-13

2013 61 1 1

77-84

2017 70 6 6

487-95

2013 6 6 6

1080-91

2016 8 Suppl 2 Suppl 2

39-45

2004 109 22 22

2749-54

2017 18 7 7

547-612

2013 128 16 16

e240-327

2018 146 1 1

68-77

2012 13 6 6

461-8

ESMO Guidelines Working Group 2012 23 Suppl 7 Suppl 7

vii155-66

2002 95 7 7

1592-600

2012 10 5 5

171-7

2015 11 4 4

407-11

2019 19 1 1

737

2010 10

337

Dexrazoxane Study Group 2006 17 4 4

614-22

1996 14 12 12

3112-20

2014 5

2008 2 2

CD003917

2004 351 2 2

145-53

2010 3 3

CD005006

2015 10 7 7

2006 114 23 23

2474-81

2013 6 3 3

420-6

2006 48 11 11

2258-62

2013 61 23 23

2355-62

2016 37 21 21

1671-80

2009 69 2 2

695-9

2012 60 23 23

2384-90

2012 5 5 5

596-603

2012 164 6 6

846-55

Byrd B3rd.Dokainish H.Edvardsen T 2016 29 4 4

277-314

2015 28 2 2

183-93

2013 26 5 5

493-8

2010 28 25 25

3910-6

2004 32 1 1

106-21

coords 2013 81 6 6

530-6

100

2011 96 2 Suppl 1 2 Suppl 1

1-52

101

National Comprehensive Cancer Network 2016

102

2000 36 2 2

517-22

103

2003 82 4 4

218-22

104

2012 12 2 2

135-42

105

2014 63 8 8

809-16

106

2008 130 5 5

688-95

107

2014 20 3 3

155-8

108

2009 100 5 5

684-92

109

2015 108 1 1

djv301

110

2008 112 6 6

1354-62

111

2016 133 1 1

31-8

112

2016 164 2 2

93-101

113

American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young.Council on Basic Cardiovascular Sciences.Council on Cardiovascular and Stroke Nursing.Council on Cardiovascular Radiology 2013 128 17 17

1927-95

114

2014 160 10 10

672-83

115

2015 33 5 5

394-402

116

International Late Effects of Childhood Cancer Guideline Harmonization Group 2015 16 3 3

e123-36